ReproCELL Inc. announces the launch of “ReproHSC”, culture medium for human hematopoietic stem cells
Yokohama, Kanagawa, Japan – ReproCELL Inc. (ReproCELL, CEO: Chikafumi Yokoyama, Ph.D. JASDAQ: 4978) announced today that the company will launch “ReproHSC”, culture medium for human hematopoietic stem cells co-developed with Nissan Chemical Industries, LTD (Tokyo, Japan, President: Kojiro Kinoshita) in December, 2013. The company will begin offering samples of “ReproHSC” in November, 2013.
Hematopoietic stem cells, found in bone marrow and cord blood, can be differentiated into many cell types such as erythrocytes, leukocytes, and blood platelets. While hematopoietic stem cell transplant (bone marrow transplant / cord blood transplant) has been utilized as an effective method of therapy for diseases such as leukemia, chronic myelodysplastic syndrome, and aplastic anemia, there are limitations due to shortage of donors.
Cord blood is a prospective source of cells for transplant because its collection is non-invasive for donors. However, the numbers of samples which can be used for transplant is limited because the volume of collected cord blood is small. In addition, the number of cells in collected cord blood is also small. Against such a background, technology development to expand hematopoietic stem cells in vitro is studied vigorously worldwide.
ReproHSC contains a novel, low molecular weight compound that dramatically increases the expansion of hematopoietic stem cells..
ReproCELL expects that ReproHSC will greatly accelerate hematopoietic stem cell research. The medium will also be targeted for for clinical applications such as cord blood transplant and regenerative medicine in future.
ReproCELL has a great interest in contributing to regenerative medicine and drug development.
For more information, please contact “firstname.lastname@example.org”.